Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ahdesmaki MJ"'
Autor:
Mosely SI; MedImmune Ltd, Cambridge, United Kingdom. moselys@medimmune.com., Prime JE; MedImmune Ltd, Cambridge, United Kingdom., Sainson RC; MedImmune Ltd, Cambridge, United Kingdom., Koopmann JO; MedImmune Ltd, Cambridge, United Kingdom., Wang DY; AstraZeneca Ltd, Cambridge, United Kingdom., Greenawalt DM; AstraZeneca Ltd, Waltham, Massachusetts., Ahdesmaki MJ; AstraZeneca Ltd, Cambridge, United Kingdom., Leyland R; MedImmune Ltd, Cambridge, United Kingdom., Mullins S; MedImmune Ltd, Cambridge, United Kingdom., Pacelli L; MedImmune Ltd, Cambridge, United Kingdom., Marcus D; MedImmune Ltd, Cambridge, United Kingdom., Anderton J; MedImmune Ltd, Cambridge, United Kingdom., Watkins A; MedImmune Ltd, Cambridge, United Kingdom., Coates Ulrichsen J; MedImmune Ltd, Cambridge, United Kingdom., Brohawn P; MedImmune LLC, Gaithersburg, Maryland., Higgs BW; MedImmune LLC, Gaithersburg, Maryland., McCourt M; MedImmune Ltd, Cambridge, United Kingdom., Jones H; MedImmune Ltd, Cambridge, United Kingdom., Harper JA; MedImmune Ltd, Cambridge, United Kingdom., Morrow M; MedImmune Ltd, Cambridge, United Kingdom., Valge-Archer V; MedImmune Ltd, Cambridge, United Kingdom., Stewart R; MedImmune Ltd, Cambridge, United Kingdom., Dovedi SJ; MedImmune Ltd, Cambridge, United Kingdom., Wilkinson RW; MedImmune Ltd, Cambridge, United Kingdom.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2017 Jan; Vol. 5 (1), pp. 29-41. Date of Electronic Publication: 2016 Dec 06.
Autor:
Rhyasen GW; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Hattersley MM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Yao Y; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Dulak A; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Wang W; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Petteruti P; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Dale IL; AstraZeneca, Macclesfield, Cheshire, UK., Boiko S; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Cheung T; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Zhang J; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Wen S; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Castriotta L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Lawson D; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Collins M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Bao L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Ahdesmaki MJ; AstraZeneca, Macclesfield, Cheshire, UK., Walker G; AstraZeneca, Macclesfield, Cheshire, UK., O'Connor G; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Yeh TC; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Rabow AA; AstraZeneca, Macclesfield, Cheshire, UK., Dry JR; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Reimer C; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Lyne P; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fawell SE; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Waring MJ; AstraZeneca, Macclesfield, Cheshire, UK., Zinda M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Clark E; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Chen H; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts. raymond.chen@astrazeneca.com.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2016 Nov; Vol. 15 (11), pp. 2563-2574. Date of Electronic Publication: 2016 Aug 29.
Autor:
Eberlein CA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Stetson D; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Markovets AA; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Al-Kadhimi KJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Lai Z; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Fisher PR; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., Meador CB; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Spitzler P; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Ichihara E; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Ross SJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Ahdesmaki MJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Ahmed A; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Ratcliffe LE; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., O'Brien EL; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., Barnes CH; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Brown H; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Smith PD; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Dry JR; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Beran G; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Thress KS; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Dougherty B; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Pao W; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Cross DA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom. Darren.Cross@astrazeneca.com.
Publikováno v:
Cancer research [Cancer Res] 2015 Jun 15; Vol. 75 (12), pp. 2489-500. Date of Electronic Publication: 2015 Apr 13.